Cargando…

Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension

Currently, no treatment can completely cure pulmonary hypertension (PH), which can lead to right ventricular failure and, consequently, death. Therefore, searching for new therapies remains important. Increased resistance in pulmonary circulation is mainly caused by the excessive contraction and pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krzyżewska, Anna, Baranowska-Kuczko, Marta, Mińczuk, Krzysztof, Kozłowska, Hanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472313/ https://www.ncbi.nlm.nih.gov/pubmed/34576212 http://dx.doi.org/10.3390/ijms221810048

Ejemplares similares

Cross-Talk between the (Endo)Cannabinoid and Renin-Angiotensin Systems: Basic Evidence and Potential Therapeutic Significance
por: Mińczuk, Krzysztof, et al.
Publicado: (2022)

Cannabidiol Improves Antioxidant Capacity and Reduces Inflammation in the Lungs of Rats with Monocrotaline-Induced Pulmonary Hypertension
por: Krzyżewska, Anna, et al.
Publicado: (2022)

Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
por: Sadowska, Olga, et al.
Publicado: (2020)

Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities
por: Baranowska-Kuczko, Marta, et al.
Publicado: (2020)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19 †
por: Malinowska, Barbara, et al.
Publicado: (2021)

Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of K(Ca)2.x and K(Ca)3.1 Channels
por: Kloza, Monika, et al.
Publicado: (2019)

Beneficial Changes in Rat Vascular Endocannabinoid System in Primary Hypertension and under Treatment with Chronic Inhibition of Fatty Acid Amide Hydrolase by URB597
por: Baranowska-Kuczko, Marta, et al.
Publicado: (2021)

Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries
por: Baranowska-Kuczko, Marta, et al.
Publicado: (2014)

Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension
por: Baranowska-Kuczko, Marta, et al.
Publicado: (2021)

GPR18-Mediated Relaxation of Human Isolated Pulmonary Arteries
por: Kozłowska, Hanna, et al.
Publicado: (2022)

Reduction of the serotonin 5-HT(1B) and 5-HT(2A) receptor-mediated contraction of human pulmonary artery by the combined 5-HT(1B) receptor antagonist and serotonin transporter inhibitor LY393558
por: Baranowska-Kuczko, Marta, et al.
Publicado: (2020)

The FAAH Inhibitor URB597 Modulates Lipid Mediators in the Brain of Rats with Spontaneous Hypertension
por: Biernacki, Michał, et al.
Publicado: (2020)

Weak Hypotensive Effect of Chronic Administration of the Dual FAAH/MAGL Inhibitor JZL195 in Spontaneously Hypertensive Rats as Revealed by Area under the Curve Analysis
por: Toczek, Marek, et al.
Publicado: (2023)

New perspectives for the treatment of pulmonary hypertension
por: Baliga, Reshma S, et al.
Publicado: (2011)

Cannabinoids in arterial, pulmonary and portal hypertension – mechanisms of action and potential therapeutic significance
por: Malinowska, Barbara, et al.
Publicado: (2018)

Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
por: Gado, Francesca, et al.
Publicado: (2018)

Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives
por: Giustozzi, Alessandra, et al.
Publicado: (2021)

Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
por: Butler, Helen, et al.
Publicado: (2009)

The Role of Cannabinoids in Bone Metabolism: A New Perspective for Bone Disorders
por: Saponaro, Federica, et al.
Publicado: (2021)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

New Drugs and Therapies in Pulmonary Arterial Hypertension
por: Shah, Aangi J., et al.
Publicado: (2023)

Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective
por: Koudstaal, Thomas, et al.
Publicado: (2020)

CB(1) receptor activation in the rat paraventricular nucleus induces bi-directional cardiovascular effects via modification of glutamatergic and GABAergic neurotransmission
por: Grzęda, Emilia, et al.
Publicado: (2016)

Updated Perspectives on Pulmonary Hypertension in COPD
por: Blanco, Isabel, et al.
Publicado: (2020)

New perspectives for mesenchymal stromal cells as an adjuvant therapy for infectious disease-associated encephalopathies
por: Lima, Maiara N., et al.
Publicado: (2021)

Considerations for Cannabinoids in Perioperative Care by Anesthesiologists
por: Laudanski, Krzysztof, et al.
Publicado: (2022)

New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

Emerging drugs of abuse: current perspectives on synthetic cannabinoids
por: Debruyne, Danièle, et al.
Publicado: (2015)

Volume Management in Pulmonary Arterial Hypertension Patients: An Expert Pulmonary Hypertension Clinician Perspective
por: Hansen, Lillian, et al.
Publicado: (2018)

Effects of the peripheral CB(1) receptor antagonist JD5037 in mono— and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension
por: Remiszewski, Patryk, et al.
Publicado: (2022)

Cannabinoid-Based Ocular Therapies and Formulations
por: Saraiva, Sofia M., et al.
Publicado: (2023)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

Use of Cannabis and Cannabinoids for Treatment of Cancer
por: Cherkasova, Viktoriia, et al.
Publicado: (2022)

Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies
por: Lima, Priscila A., et al.
Publicado: (2022)

Why Multitarget Vasodilatory (Endo)cannabinoids Are Not Effective as Antihypertensive Compounds after Chronic Administration: Comparison of Their Effects on Systemic and Pulmonary Hypertension
por: Remiszewski, Patryk, et al.
Publicado: (2022)

Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy
por: Abate, Giulia, et al.
Publicado: (2021)

Future Aspects for Cannabinoids in Breast Cancer Therapy
por: Kisková, Terézia, et al.
Publicado: (2019)

Cannabinoids and Cannabinoid Receptors: The Story so Far
por: Shahbazi, Fred, et al.
Publicado: (2020)

New Prospect for Cancer Cachexia: Medical Cannabinoid
por: Wang, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k2a1o5qs0pu61b1tb4g419jftm